The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
click on link and listen
https://www.proactiveinvestors.co.uk/companies/news/910912/revenue-guidance-from-optibiotix-as-it-eyes-nasdaq-listing-910912.html
i need 23p to breakeven , i listened to much to the ausie and ritson, i wont topup to busy with OPTI
("TP Group" or the "Company" or the "Group")
Submarine Oxygen Generating Devices Order
TP Group (AIM: TPG), the providers of mission-critical solutions for a more secure world, announces that it has secured a new order worth approximately GBP1.0 million from the Ministry of Defence ("MoD") to supply it with oxygen generating devices.
This order is for a further 750 multi-purpose oxygen generators, which are supplemental to the Company's other large atmosphere management systems which the Company currently supplies to the MoD and other global customers.
These devices will be supplied to the Royal Navy during 2020 as part of the estimated GBP22m framework contract previously entered into between TP Group and the MoD to manage equipment availability and provide spares for air purification systems, as announced by the Company on 3 April 2017.
Phil Cartmell, Chief Executive Officer of TPG commented:
"We are very pleased to see a further significant order under the long-standing framework agreement between the MoD and TP Group. This latest order highlights the enduring value of these arrangements and further illustrates how the Group provides long-term support and ancillary solutions alongside major systems, to provide an all-round service to our key customers."
08 January 2020
OptiBiotix Health Plc
("OptiBiotix" or the "Company")
Human study shows formulation with LP(LDL) (R) reduces high blood pressure
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), in partnership with Nutrilinea Srl. ("Nutrilinea") has completed a successful human study for a new food supplement formulation containing LP(LDL) (R) and has shown the product can reduce high blood pressure (hypertension).
The study was part of an agreement (RNS: 20 May 2019) with Nutrilinea to fund the development, manufacture, and carrying out of human studies for a new blood pressure product in return for 12 months exclusivity from the date the data was made available from the human study (18 December 2019) for the European market. ProBiotix has exclusivity for the UK and all other markets outside Europe.
The three month study of 40 patients was carried out by the Center of Diabetes and Metabolic Diseases, Department of Internal Medicine and Therapeutics, University of Pavia and Fondazione IRCCS Policlinico San Matteo, Pavia, Italy and showed statistically significant reductions in both systolic, diastolic blood pressure levels, and cholesterol levels. The results of this study are consistent with ProBiotix's initial study conducted at the University of Reading which showed a statistically significant reduction in both blood pressure and cholesterol in volunteers taking LP(LDL) (R) (Costabile et al., 2017).
The European Cardiovascular Society reported in 2016 that the combination of lowering LDL cholesterol and systolic blood pressure has the potential to "dramatically reduce" a person's lifetime risk of cardiovascular disease. Hypertension is a global healthcare issue and is one of the strongest risk factors for almost all cardiovascular diseases. The fact that it does not have obvious symptoms has led doctors to call hypertension a 'silent killer'. Studies conducted in Europe and in the United States suggest that, under new hypertension guidelines, a large percentage of the adult population may be considered hypertensive: some 14 million people in the UK and over 100 million in the US.
https://www.heart.org/en/news/2018/05/01/more-than-100-million-americans-have-high-blood-pressure-aha-says
Steve Prescott, Chief Executive Officer of ProBiotix, commented: "We are very pleased to have partnered with Nutrilinea who covered the cost of the product development, manufacturing, and the human study. Because hypertension effects millions of people globally and is a serious risk factor for cardiovascular disease, we are excited to offer a natural product that has been clinically proven to lower hypertension. Adding this new formulation to our portfolio of existing products that target cholesterol reduction, CholBiome(R) and CholBiome(R) x3, allows ProBiotix to offer a b
why not
19 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
SlimBiome(R) distribution agreement for Germany
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered into an exclusive agreement with Draco Ingredients GmbH ("Draco") to distribute OptiBiotix's SlimBiome(R) proprietary weight management technology in Germany. Market exclusivity is linked to minimum order quantities in order to maximise the financial return for both parties.
Draco Ingredients (www.draco-ingredients.de) is a German food ingredient company established in 2001 focusing on the distribution of mainly dairy based ingredients to a broad spectrum of customers active in segments such as dairy, sports and medical nutrition.
This agreement is another step in extending the geographical reach and sales of SlimBiome(R). This is consistent with our strategy of increasing the number of geographies and applications SlimBiome(R) is used in as an ingredient. This builds revenue potential and brand recognition and reduces commercial risk.
Andre Wittke, General Manager of Draco Ingredients, commented: "We are delighted to have the opportunity of partnering with Optibiotix and look forward to building a presence for SlimBiome(R) in Germany by leveraging on the strengths of both organisations. We see SlimBiome's unique value proposition (patented solution backed by clinical and consumer studies and supported by EFSA-approved claims) as being a key driver of the sale of this functional ingredient to German customers in the near future."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce this agreement with Draco Ingredients to service the German market. The timing of this agreement fits particularly well with our recent focus on creating the building-blocks necessary to accelerate and expand our reach to customers globally. This deal builds on the work done in 2019 to qualify multiple manufacturers of SlimBiome(R) in Europe and around the world (e.g Zeon: India, Agropur: USA) to de-risk our supply-chain in the case of a hard Brexit and give us access to one of Europe's largest economies."
17 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Anthem BioPharma launches two products formulated with SlimBiome(R) to the Indian market
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skincare, announces the commercial launch of two products formulated with SlimBiome(R) to the Indian market in partnership with Anthem BioPharma and Zeon Life Sciences.
Anthem BioPharma (www.anthembiopharma.com), an Anthem Biosciences Pvt Ltd company, is a fully integrated Indian Pharmaceutical and Biotechnology company with a turnover of GBP90 million in FY 2019-20 and launched two products formulated with SlimBiome(R) to the Indian market on 16 December 2019. The products are 1) Metalite - a supplement to aid with effective weight management and 2) Metalite Pro - a high protein meal replacement (www.metalitepro.com).
Pratik Girish Ligade, Marketing & Sales Business Head - Diabetology, commented: "India is currently one of the most attractive potential markets for the health and wellness industry due to its large, fast urbanizing population. Increasing stress and unhealthy lifestyle, has made nearly 1 out of 4 adults overweight. The main reasons behind this alarming situation is an increase in the consumption of processed food, lower levels of physical activity and increased professional and personal life pressures. Truncal obesity in adults and teens, unhealthy food choices and contamination of food, water and air in cities is creating a perfect storm of lifestyle diseases. Consumers are becoming aware of the serious health risks resulting from their new lifestyle choices and are willing to do something about it. As a result, there is an increase in wellness products and dietary supplements product offerings targeting weight loss, however, there is hardly any clinically tested meal replacement product available in India. It gives Anthem a great opportunity to make an impact in this space, and we believe SlimBiome(R) will play an important role in addressing the obesity pandemic that continues to increase. We chose SlimBiome(R) because it is scientifically formulated and clinically proven to function in weight management applications."
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are very pleased to announce this commercial launch in partnership with Anthem BioPharma and Zeon Life Sciences, the exclusive manufacturer of SlimBiome(R) in India. This launch is the start of recurrent revenues in India and we are confident in our capacity to replicate similar deals in other markets in the near future now that we have production partners in North America, the UK, Europe and India.
12 December 2019
COLUMBUS ENERGY RESOURCES PLC
("Columbus" or the "Company")
Update on Saffron well - South West Peninsula, Trinidad
Columbus, the oil and gas producer and explorer with operations in Trinidad and Suriname, is pleased to provide an update on the progress of the Saffron well, currently being drilling in the South West Peninsula, Trinidad.
The drilling of the Saffron well is continuing as planned with encouraging results to date. The 8 1/2 " pilot hole was successfully drilled to the planned depth and encountered hydrocarbon bearing zones within the tertiary target. This provided the Company with the knowledge and confidence to widen to the 17 1/2 " hole size and set 13 5/8" casing, which would allow future testing of encountered oil zones on a successful completion of the well.
Whilst drilling the 12 1/4 " section, further shows of oil bearing intervals have been encountered within the secondary target as well as high formation pressures. This has required careful measures to ensure the wellbore is in a stable condition whilst continuing to drill. The Company is currently drilling ahead the main 8 1/2 " hole section with which it is planned to reach our prognosed Lower Cruse primary target. On achievement of the TD (Total Depth) criteria the Company intends to log and perform production testing of the well, as appropriate.
The Company will update, when appropriate, as drilling continues.
Leo Koot, Executive Chairman of Columbus, commented:
"The drilling of the Saffron well is progressing towards our total depth target and we have been encouraged by various oil and gas shows throughout the drilling campaign. I have been at the rig-site during the critical phases of the well campaign and continue to supervise day to day operations. The knowledge of the formations and rig systems gained so far from drilling the Saffron well is being applied to the final stages as we reach the primary target and will also prove valuable information for the future wells within the Southwest Peninsula including any development drilling. The Company looks forward to updating the market as appropriate."
09 December 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
Distribution agreement for CholBiome(R)(x3) in the Philippines
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, announces that its fully-owned subsidiary ProBiotix Health Ltd. ("ProBiotix"), has signed an exclusive agreement with CTC Far East Philippines, Inc. ("CTC"), a subsidiary of the CTC Group, for the distribution of ProBiotix's proprietary formulation CholBiome(R)x3 in the Philippines.
Under the terms of the agreement, ProBiotix will supply CholBiome(R)(x3) , featuring its cholesterol and blood pressure-reducing probiotic strain Lactobacillus plantarum LP(LDL) (R), to CTC for its distribution in the Philippines. Exclusivity is subject to minimum order quantities and a multiyear business plan in an attempt to improve security of income and revenue growth.
"CTC Group (CTC), is the global business network group of the Koen Visser Corporation. CTC is active in Europe, Africa, South and Central America, Caribbean and Asia with head office located in Amsterdam, The Netherlands. CTC Group is a global life science partner-provider of innovative product solutions for food, beverage, personal care products, and health and wellness."
The Philippines is a country with an expanding population of over 100 million and an emerging economy with annual GDP growth rates above 6% sustained over the last 5 years (World Bank). Cardiovascular disease is the leading cause of death in the country, with high blood pressure affecting almost 20% of its population (WHO).
Steve Prescott, CEO of ProBiotix, commented: "We are pleased to announce this agreement with CTC, which will expand ProBiotix's presence in the emerging Asia-Pacific region. CTC was chosen as our partner for CholBiome(R)(x3) product introduction in the Philippines because of their extensive knowledge of the local market and consistent track record successfully launching new products."
GoFigure(R) and SlimBiome(R) commercial updates
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered into three new exclusive distribution agreements which seek to extend the global reach of its SlimBiome(R) and GoFigure(R) products:-
1. Extensor: Extensor is OptiBiotix's exclusive partner in Poland for distributing its GoFigure(R) product range (RNS: 22 May 2019). OptiBiotix has signed a further agreement which grants Extensor exclusive rights to distribute SlimBiome(R) in Poland for a period of 12 months with continued exclusivity subject to performance review. The agreement recognises the successful launch of GoFigure products containing SlimBiome into the Polish market http://www.gofigure.pl/ and allows Extensor to extend the use of SlimBiome(R) into its own range and partner products.
2. Epic Ingredients: The Company has signed an exclusive distribution agreement with Epic Ingredients Sdn Bhd ("Epic Ingredients") to distribute SlimBiome(R) in Malaysia and Singapore. Exclusivity is subject to minimum order quantities and a requirement to place a first order within 4 months of signing the agreement. Epic Ingredients was incorporated in 1998 as a pharmaceutical service company with its registered office in Malaysia. Their focus is on the distribution of active pharmaceutical ingredients (APIs), excipients and nutraceutical raw materials providing complete distribution and warehousing facilities
3. Supplemed Solution Sdn Bhd: The Company has signed an exclusive distribution agreement with Supplemed Solution Sdn Bhd ("Supplemed"), a subsidiary of Epic Ingredients, to distribute OptiBiotix's own label GoFigure(R) consumer weight management products in Malaysia and Singapore. Exclusivity is subject to minimum order quantities and a requirement to place a first order within 4 months of signing the agreement. Supplemed is a subsidiary of Epic Ingredients which focuses on the import and distribution of nutraceuticals backed by human studies.
These agreements are another step in in extending the geographical reach and sales of both SlimBiome(R) and SlimBiome containing products like GoFigure. This is consistent with our strategy of increasing the number of geographies and applications SlimBiome is used in both as an ingredient, and within GoFigure own brand and partner white label brands. This builds revenues and brand recognition.
The agreements for Malaysia and Singapore arise from the publicity and interest generated from SlimBiome(R) Medical winning the NutraIngredients award for Best Weight Management Ingredient of the Year for Asia 2019.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce this extension of our partnership with Extensor to service the Polish market. They have proven to be a very
i can wait
sorry should have said it was thanks to PRIMAL on advfn for the write up
SOH:
“Hi,
I had a couple of offers from investment groups for SBTX shares and given it would add value to the SBTX shareholding and wouldn’t impact on the price (it rose on both occasions) felt the money would support the stocking of retailers and the 6 figure SlimBiome order (as we have to buy the ingredients first). We would have been Ok but interest is growing quickly and I wanted some contingency in place in case demand for the products was high and they needed rapid restocking. I didn’t want to risk having a retailer growing sales and us not being in a strong position with stock. This is unusual activity and the extra funds gives us added contingency if required.
This represents a very small % of our SBTX holding which we paid about £750k for and is now still worth over £8.5m.”
Opti are also in talks with one of the WORLDS BIGGEST US retailers:
SOH:
“With the retailers. There is a lot going on with multiple retailers in the UK and US. One has stated they will have a TV campaign promoting the product so we should have high exposure in the New Year. We will contribute to some of the costs. I anticipate at least one, possibly 3 retailers in Q1 2020. If we get the US retailer confirmed this is one of the worlds biggest retailers. Just to caveat with retailers nothing is guaranteed until they are in the shops.”
The demand for Slimbiome is very high which is why they have sold SBTX IMO, Slimbiome will be a big earner for us!
listen to this
https://webcasting.brrmedia.co.uk/broadcast/5db18d5734a3cf1389e7f865
OptiBiotix Health PLC (‘OptiBiotix’), a life sciences business developing compounds to tackle obesity, cardiovascular disease and diabetes, has announced that it has completed pharma level Good Manufacturing Practice (‘GMP’) validation for the manufacture of its revolutionary probiotic ingredient LPLDL®, having completed the requirements to be manufactured under strict protocols to pharmaceutical standards.
LPLDL® achieved this milestone, which marks it out as a robust solution for the growing consumer health and wellness markets. As many businesses seek out products that demonstrably meet stringent safety, clinical efficacy and traceability criteria, GMP identifies LPLDL®, supplied by fully owned subsidiary ProBiotix Health Ltd (‘ProBiotix’), as an elite class of probiotics that meets the standard.
Steve Prescott, CEO at ProBiotix commented: “GMP is the gold standard of ingredient manufacturing; it’s currently available for only a small number of probiotic ingredients, supporting it’s characteristics as a premium probiotic. We’re delighted that LPLDL® has achieved this milestone. The ingredient fits into a spectrum of pharmaceutical, dietary supplement, and biotherapeutic roles; truly raising the bar for the probiotic category – a sector that is continuing to see strong growth across the board.
“GMP validation demonstrates that ProBiotix consistently puts safety, quality and development at the forefront to deliver high quality ingredients. Particularly significant in an industry that relies on proven demonstrable safety and accountability, this milestone is another key step forward in the continual commercialisation of LPLDL®.”
LPLDL® impacts positively on the gut microbiome using a naturally occurring strain of the bacterial species Lactobacillus plantarum. This new certification makes it ideal for use within pharmaceutical and biotherapeutic products, by improving blood lipid profiles and blood pressure using unique probiotic screening and research to offer a natural, science-backed approach to physical health.
ProBiotix is committed to investment and development, strengthening its offering as demonstrated by this GMP validation to provide a truly desirable ingredient to the pharmaceutical sector. Validation demonstrates that the raw material is manufactured to exacting health standards. LPLDL® finds widespread use in a number of wellness applications, driving considerable consumer-led value through the supply chain.
For more information on LPLDL® please visit http://optibiotix.com/product/lpldl/
Categories
Blogs
Commercial Media
Events
News
Scientific Media
Recent Posts
LPLDL® successfully completes pharma level GMP validation
SlimBiome® to showcase at SupplySide West
GoFigure® scoops top consumer award
OPTIBIOTIX ONLINE STORE CELEBRATES SUCCESSFUL FIRST YEAR
OptiBiotix drives growth of SlimBiome® technology with new distribution deal
Leave a Reply
Your email ad
WOW it is without doubt DYOR though
7 October 2019
TP Group plc
("TP Group" or the "Company" or the "Group")
Military satellite communications contract
TP Group (AIM: TPG), the providers of mission-critical solutions for a more secure world, announces that it has been appointed as a key part of the team which has won the Ministry of Defence ("MOD") Skynet Client Side Support ("CSS") contract.
This arrangement has been confirmed with the issue of the first task orders, with a committed value of GBP1.5million to be delivered over the next 12 months.
Working with the prime contractor for CSS, PA Consulting, TP Group is providing technical assurance, approvals, analysis and cost estimation expertise to the third largest acquisition project in MOD. The full CSS contract is planned to last for 5 years and has an advertised value of GBP150m.
Phil Cartmell, Chief Executive Officer of TP Group, commented:
"We are very pleased to join the PA Consulting team for such a prestigious project in military satellite communications and technology. Following the acquisition of Sapienza Consulting earlier this year, this win cements the Company's role as a trusted partner to MOD in this high technology field and positions the Group for other major space programme work throughout Europe."
hi i think the NHS i think doctors can write scripts if the product has medical status, dont quote me on that i am sure i read it some were.
please pull me up if i am wrong
GoFigure(R) distribution agreement for Southern Africa
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered into a one year exclusive distribution agreement with a South African partner ("The Partner") to distribute its own label GoFigure(R) consumer weight management products in South Africa and neighbouring countries.
The agreement grants The Partner the exclusive rights to import, market and distribute OptiBiotix's GoFigure(R) range of products containing its award-winning SlimBiome(R) weight management technology. This agreement has been signed accompanied by minimum order quantities to be placed within three and 12 months of signing to retain exclusivity.
The Partner wishes to remain anonymous until the official launch date of the GoFigure(R) brand in South Africa has been confirmed. The Partner has more than 20 years of experience in the pharmaceutical and health & wellness markets and has successfully commercialised and promoted a wide range of products to a broad network within the region, spanning the full supply chain.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics division, commented: "We are pleased to announce the signing of this exclusive distribution deal for the commercialisation of our GoFigure(R) products in South Africa and neighbouring countries (a market estimated to be worth ZAR3.8billion in 2016 source: https://pharmadynamics.co.za/sas-health-supplement-market-booming/). The agreement is another strategic step to take OptiBiotix's GoFigure(R) products to international markets which is important as it builds brand recognition, enhancing brand value and creates a further demand for SlimBiome(R), the functional ingredient within GoFigure(R) products. This is an exciting second step in taking OptiBiotix's own label GoFigure(R) products to international markets and follows on the announcement of an earlier deal in Poland (RNS: 22 May 2019)."
MM,s making a meal of things this morn, how can they get away with it ?